Evidence map›Paper›PMID 31588407›Full record

ArticleCurrent transplantation reports2019

Measuring alloreactive B cell responses in transplant recipients.

Suheyla Hasgur, Anna Valujskikh

Abstract read
In one paragraph

Article in Current transplantation reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Suheyla HasgurDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Anna ValujskikhDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.

Funding

Surgery CoreP01AI087586 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI VALUJSKIKH, ANNA · 2010 to 2019
$17.2M
Designing induction therapies to target memory T cells in high risk recipientsR01AI113142 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI VALUJSKIKH, ANNA · 2016 to 2025
$4.4M
NIAID NIH HHS P01 AI087586NIAID NIH HHS R01 AI113142
6 · The paper itself

Abstract

purposeDespite advanced immunosuppression, donor-specific antibodies (DSA) remain the leading cause of acute and chronic transplant tissue injury. Comprehensive evaluation of anti-donor humoral immune responses is critical for successful prevention, diagnosis and treatment of antibody-mediated rejection. This review summarizes the evolution of techniques used for this purpose in experimental and clinical transplantation. RECENT

findingsFor decades, measuring DSA serum levels was the only way to assess recipient humoral immunity. Recently, the interest shifted from quantifying circulating DSA to the analyses of various B cell subsets and most importantly, of donor antigen-specific B cells. State-of-the-art approaches have been developed by studies of model antigens, infectious agents and autoimmunity. These methods are now being adopted by the transplantation field. SUMMARY: The complexity of humoral immunity caused by organ transplantation necessitates complementary approaches assessing both DSA and various B cell subsets to successfully target antibody-mediated rejection.

Indexed as

antibody mediated rejectionB cellsdonor specific antibodyorgan transplantation

Identifiers

PMID31588407
PMCPMC6777871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.